Bristol Myers Squibb Stock Profit Margin
| BMYB34 Stock | BRL 355.25 12.45 3.63% |
Bristol Myers Squibb fundamentals help investors to digest information that contributes to Bristol Myers' financial success or failures. It also enables traders to predict the movement of Bristol Stock. The fundamental analysis module provides a way to measure Bristol Myers' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bristol Myers stock.
Bristol |
Bristol Myers Squibb Company Profit Margin Analysis
Bristol Myers' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Bristol Myers Profit Margin | 0.14 % |
Most of Bristol Myers' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Bristol Myers Squibb has a Profit Margin of 0.1371%. This is 101.22% lower than that of the Healthcare sector and 99.12% lower than that of the Drug Manufacturers - Major industry. The profit margin for all Brazil stocks is 110.8% lower than that of the firm.
Bristol Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol Myers' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bristol Myers could also be used in its relative valuation, which is a method of valuing Bristol Myers by comparing valuation metrics of similar companies.Bristol Myers is currently under evaluation in profit margin category among its peers.
Bristol Fundamentals
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0613 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 1.04 T | |||
| Shares Outstanding | 2.13 B | |||
| Price To Earning | 50.79 X | |||
| Price To Book | 5.00 X | |||
| Price To Sales | 18.62 X | |||
| Revenue | 46.16 B | |||
| Gross Profit | 36.02 B | |||
| EBITDA | 18.54 B | |||
| Net Income | 6.33 B | |||
| Cash And Equivalents | 29.36 B | |||
| Cash Per Share | 17.95 X | |||
| Total Debt | 39.6 B | |||
| Debt To Equity | 159.70 % | |||
| Current Ratio | 3.88 X | |||
| Book Value Per Share | 15.38 X | |||
| Cash Flow From Operations | 16.21 B | |||
| Earnings Per Share | 15.61 X | |||
| Price To Earnings To Growth | 2.41 X | |||
| Number Of Employees | 41 | |||
| Beta | 0.42 | |||
| Market Capitalization | 812.44 B | |||
| Total Asset | 109.31 B | |||
| Z Score | 12.0 | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 109.31 B | |||
| Last Dividend Paid | 2.19 |
About Bristol Myers Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myers using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Bristol Stock
When determining whether Bristol Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.